Stellenbosch University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Stellenbosch South Africa (1918)

Organization Overview

First Clinical Trial
2001
NCT00217230
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Pediatrics and Child Health, Faculty of Health Sciences, University of Stellenbosch | Dept of Family Medicine & Primary Care, University of Stellenbosch | Desmond Tutu TB Centre, Dept. Pediatrics and Child Health, Stellenbosch University | Desmond Tutu TB Centre, Stellenbosch University | Karl Bremmer Hospital, Tygerberg, South Africa | Tiervlei Trial Center and University of Stellenbosch | Tiervlei Trial Center, Stelennbosch University, South Africa | Tiger Trial Centre, Karl Bremmer Hospital, Tygerberg, South Africa | Tygerberg Hospital | Tygerberg Hospital and Stellenbosch University | Tygerberg Hospital, Cape Town, South Africa | Tygerberg Hospital Respiratory Research Unit, South Africa | University of Stellenbosch

Active Ingredients

Drugs in Phase 4 Trials (10)

citalopram (celexa) (1 trial)

escitalopram (lexapro) (1 trial)

fluoxetine (prozac) (1 trial)

fluvoxamine (luvox) (1 trial)

icosapent ethyl (vascepa) (1 trial)

lactobacillus plantarum (1 trial)

lopinavir (Kaletra) (2 trials)

pregabalin (lyrica) (1 trial)

ritonavir (Norvir) (2 trials)

sertraline (zoloft) (1 trial)

Drugs in Phase 3 Trials (36)

abacavir (ziagen) (2 trials)

acetylcysteine (mucomyst) (1 trial)

atorvastatin (lipitor) (1 trial)

attenuated live hepatitis A vaccine (1 trial)

bacille calmette-guerin (7 trials)

bedaquiline (sirturo) (5 trials)

delamanid (3 trials)

didanosine (videx) (1 trial)

efavirenz (sustiva) (1 trial)

egg (1 trial)

ethambutol (myambutol) (3 trials)

ethionamide (trecator) (1 trial)

ferrous fumarate (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

isoniazid (nydrazid) (8 trials)

kanamycin (Kantrex) (1 trial)

lactobacillus delbrueckii (1 trial)

lamivudine (epivir) (2 trials)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (1 trial)

live attenuated influenza virus vaccine (Flumist) (1 trial)

meloxicam (mobic) (1 trial)

moxifloxacin (avelox) (2 trials)

mtbvac (1 trial)

nevirapine (viramune) (1 trial)

pretomanid (2 trials)

pyrazinamide (Aldinamide) (4 trials)

pyridoxine (1 trial)

rifampin (3 trials)

rifapentine (priftin) (2 trials)

sulfamethoxazole (gantanol) (1 trial)

sutezolid (1 trial)

terizidone (1 trial)

trimethoprim (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 2 Trials (11)

belinostat (beleodaq) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

clofazimine (lamprene) (1 trial)

dolutegravir (tivicay) (2 trials)

metformin (glucophage) (1 trial)

nicotine (nicorette) (1 trial)

paclitaxel (taxol) (1 trial)

pamrevlumab (1 trial)

pomalidomide (pomalyst) (1 trial)

varenicline (chantix) (1 trial)

Drugs in Phase 1 Trials (1)

lessertia fructescens (1 trial)

Drugs in Other Trials (14)

amino acids (Freamine) (1 trial)

bifidobacterium infantis (1 trial)

chlorhexidine (hibitane) (1 trial)

fumaric acid esters (2 trials)

galactooligosaccharide (1 trial)

iron sulfate (1 trial)

laminaria (1 trial)

maltodextrin (2 trials)

mannitol (Osmitrol) (1 trial)

misoprostol (cytotec) (1 trial)

nyaditum resae (1 trial)

oxygen (1 trial)

sorghum (1 trial)

urofollitropin (Metrodin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Communicable Diseases (Phase 3)

Compulsive Personality Disorder (Phase 4)

Condylomata Acuminata (Phase 3)

Disease (Phase 4)

Dyskinesias (Phase 4)

Enterocolitis (Phase 3)

Enterocolitis, Necrotizing (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Fibrosis (Phase 2)

HIV Infections (Phase 4)

Idiopathic Pulmonary Fibrosis (Phase 2)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 3)

Inflammation (Phase 3)

Influenza, Human (Phase 3)

Latent Tuberculosis (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Obsessive-Compulsive Disorder (Phase 4)

Premature Birth (Phase 3)

Pulmonary Fibrosis (Phase 2)

Recurrence (Phase 3)

Schizophrenia (Phase 4)

Tardive Dyskinesia (Phase 4)

Tobacco Use Disorder (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial APIs: 72